LONDON, UK: Oncimmune Holdings has sold its diagnostic business, including the EarlyCDT® Lung blood test and antibody platform, to Freenome Holdings, a US-based biotechnology company developing a multiomics platform for early cancer detection and intervention. The deal is worth £13M in cash and is expected to be completed in the coming weeks. Oncimmune will retain…
All posts tagged Oncimmune
Oncimmune signs agreement to profile patients
LONDON, UK: Oncimmune Holdings has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The initial phase of this project, including the reporting of profiled data, is scheduled to complete by the end of calendar year 2021. Under this agreement, Oncimmune…